Skip to main content
. 2017 Dec 15;9(12):5461–5472.

Figure 1.

Figure 1

The expression and clinical significance of SUMO1P3 in colon cancer. (A) SUMO1P3 expression was measured by qPCR assay and normalized to GAPDH in 120 pairs of colon cancer tissues and corresponding non-tumor tissues. (B and C) Comparisons of SUMO1P3 levels in colon cancer patients at different stages (I/II stage, n = 63; III/IV stage, n = 57) (B) and with (n = 60) or without (n = 60) lymphatic metastasis (C). (D) Association between SUMO1P3 expression and MVD determined by CD34 expression. CD34 expression was evaluated by IHC assay in colon cancer tissues from SUMO1P3 high-expression (n = 80) and low-expression (n = 40) groups. Magnification: 100 ×. (E) Five-year survival rate of colon cancer patients with high expression (n = 80) and low expression (n = 40) of SUMO1P3. All data are represented as the mean ± SD of three replicates. *P < 0.05, **P < 0.01.